INTRODUCTION
Renal cell carcinoma (RCC) is the eighth most commonly diagnosed cancer in the United States, with an estimated 61,000 new cases and 14,000 deaths in the year 2015. 1 Several analyses of the Surveillance, Epidemiology, and End Results database suggest that African American (AA) patients with RCC have decreased overall survival compared with Caucasian patients regardless of age, sex, disease stage, or histologic subtype. [2] [3] [4] Furthermore, the survival disadvantage for AA patients may have been more prominent in the last decade compared with that in the 1990s, 2, 5 suggesting that AA patients have had less benefit from the introduction of targeted therapy than Caucasian patients. Some studies have suggested that the survival disparity observed in AA patients may be related to access to treatment and lower rates of nephrectomy, even among patients with metastatic RCC. 3, 6, 7 However, the differential rates of nephrectomy and survival between races could be related to several factors, including socioeconomic status, access to care, comorbidities, performance status, disease burden, and, potentially, tumor biology.
The survival rates for patients with metastatic RCC were stable for many years but have improved since the advent of targeted therapies for RCC. 5, 8 In 2005, the US Food and Drug Administration approved sorafenib, the first vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor (TKI) for RCC. That approval was closely followed by the approval of several additional targeted agents for advanced RCC, including other VEGFR-TKIs as well as mammalian target of rapamycin (mTOR)-inhibitor therapies. It remains unclear how the availability of these novel agents has influenced the racial disparity in survival among patients with advanced RCC or whether the survival of AA patients with advanced RCC has improved as much as that of Caucasian patients.
For this study, we used a large national database to assess whether the advent of targeted therapy has changed the disparity in survival between AA and Caucasian patients. To that end, we asked whether the survival of AA patients with advanced RCC has improved since the implementation of targeted therapy and how any improvement in survival compares with that observed in Caucasian patients.
MATERIALS AND METHODS
The National Cancer Data Base (NCDB) is a nationwide, hospital-based, oncology outcomes database that captures approximately 70% of all newly diagnosed cancer cases in the United States in over 1500 hospitals. 9 The NCDB is a joint project of the American Cancer Society and the Commission on Cancer of the American College of Surgeons. Available data in the NCDB include patient demographics, facility information, tumor characteristics, receipt of treatment, and outcomes. The data used in the study are derived from a deidentified NCDB file; therefore, the study was approved for exempt status by the University of North Carolina Institutional Review Board. The American College of Surgeons and the Commission on Cancer have not verified and are not responsible for the analytic or statistical methodology used or the conclusions drawn from these data by the investigators.
The NCDB was queried for all patients with stage IV RCC who were diagnosed between 1998 and 2011. All included patients had stage IV disease at the time of diagnosis. Patients were included in the analysis if their race was designated as Caucasian or AA. Patients were categorized into 2 cohorts based on year of diagnosis. Patients who were diagnosed between 1998 and 2004 were defined as the "pretargeted therapy" group, because their diagnosis occurred before the widespread use of targeted therapy for advanced RCC. Patients who were diagnosed between 2006 and 2011 were defined as the "post-targeted therapy" group. Patients who were diagnosed in 2005 were not included, because the use of targeted therapy was more limited in that period (Fig. 1) . Survival outcomes data were evaluated in 2014 in this data set; therefore, the maximum follow-up for the 2011 cohort was 3 years.
Demographic variables included age, sex, race, education, household income, insurance status, and comorbidity score. According to the NCDB, education was defined as the percentage of adults in the patient's zip code who did not graduate from high school and was categorized as 29%, from 20% to 28.9%, from 14% to 19.9%, and <14%. Household income was defined as the median annual household income in each patient's zip code and was defined as $46,000, from $35,000 to $45,999, and <$35,000. Insurance status was categorized as private, Medicare, managed care, Medicaid or other government, or uninsured. Comorbidities were estimated using the Charlson-Deyo comorbidity index, with scores of 0 (no comorbid conditions), 1, or 2 according to the NCDB. 10 The facility type in which each patient was treated was categorized into 3 categories: communitybased practices, comprehensive community cancer centers, and academic or research programs.
Staging was defined according to the American Joint Committee on Cancer tumor, lymph node, metastasis (TNM) classification criteria based on pathologic stage, if available, or clinical stage if pathologic stage was unavailable. Histology was defined as clear cell, papillary, chromophobe, or unknown. Grade was defined as 1 (well differentiated) through 4 (undifferentiated). Patients were defined as having received a nephrectomy if they had undergone a complete, total, simple, radical, or any nephrectomy according to the NCDB as well as nephrectomy not otherwise specified. Targeted therapy, including receptor TKIs that target the VEGF pathway and mTOR inhibitors, is categorized in the NCDB as chemotherapy. The NCDB does not annotate the type of chemotherapy received; therefore, we defined the receipt of systemic therapy as including both targeted therapy and cytotoxic chemotherapy with presumably low rates of cytotoxic chemotherapy use because of low efficacy in RCC. Receipt of systemic therapy did not include immunotherapy.
STATISTICAL ANALYSIS
Chi-square tests were used to analyze differences between races for categorical variables, and a t test was used to compare age. For each year between 1998 and 2011, the rates of systemic therapy receipt were compared between races using chi-square tests. The Kaplan-Meier method was used to estimate survival, including survival probabilities at 3 years and 5 years; and the log-rank test was used to compare differences in survival between the 2 periods separately by race. Survival was calculated from the date of diagnosis to the date of either last contact or death. Multivariable Cox regression models were used to compare differences in survival by race separately for each period while controlling for potential confounders; hazard ratios (HRs) for death are reported. Both receipt of nephrectomy and receipt of systemic therapy were treated as time-varying covariates in the models to control for the time to initiation of systemic therapy and the time to nephrectomy. All statistical tests were 2-sided, and P values < .05 were considered statistically significant. The statistical software package SAS version 9.4 (SAS Institute, Inc, Cary, NC) was used for all analyses.
RESULTS
In total, 48,846 patients with stage IV RCC were identified in the NCDB who were diagnosed during 1998 through 2004 and during 2006 through 2011. Ninety percent of these patients were Caucasian, and 10% were AA. Demographics of the population by race are listed in Table 1 . AA patients were younger than Caucasian patients (P < .01). AA patients were more likely to be female, uninsured or Medicaid/other government Original Article insured, and treated in an academic or research facility (P < .01 for all). AA patients were also more likely to have papillary histology and were less likely to undergo a nephrectomy (P < .01 for both). AA patients were more likely to have distant metastatic disease (P < .01). The difference in comorbidity scores between races was not significant (P 5 .06).
Patients in the post-targeted therapy period were much more likely to receive systemic therapy than patients in the pretargeted therapy period (47% vs 17%; P < .01). Systemic treatment increased dramatically with time, but rates of implementation did not differ by race (P .08 for each year) (Fig. 1) . A similar percentage of Caucasian and AA patients received systemic therapy overall (P 5 .97). However, AA patients were slightly less likely than Caucasian patients to receive systemic therapy in the posttargeted therapy period (46% vs 48%; P 5 .04).
The 3-year and 5-year survival of all patients with advanced RCC improved significantly between the pretargeted therapy period and the post-targeted therapy period, with an improvement of 1.4 months for Caucasians and 0.8 months for AA patients (P < .01 for both) ( Table  2 ). The median follow-up was 7.0 years for the pretargeted therapy period and 2.6 years for the post-targeted therapy period. There was no significant interaction between race and time period on survival (P 5 .15). To control for access to care, which has been postulated as a reason for disparate survival rates in the past, we then restricted the survival analysis to patients who actually received systemic therapy. Among these patients, survival rates were higher than in the total population, and there remained a statistically significant improvement in survival over time for both Caucasians and AAs. When the survival analysis was further restricted to only those who received systemic therapy and had clear cell histology, the improvement in survival over time in AA patients lost statistical significance for AAs (P 5 .06), although the sample size was drastically reduced in this subset. The magnitude of the benefit was roughly similar between the 2 groups, with Caucasians having a 1.9-month (or 19.2%) improvement in overall survival between the 2 time periods and AAs having a 1.6-month (or 20.5%) improvement. In those who had papillary histology, there was no statistically significant change in survival across time in either race. AA patients had decreased overall survival compared with Caucasian patients, and the disparity remained relatively stable over time, with an unadjusted HR for death of 1.13 (95% confidence interval [CI], 1.08-1.18) in the pretargeted therapy era and an HR of 1.18 (95% CI, 1.13-1.23) in the post-targeted therapy era (Fig. 2) . After adjusting for age, sex, income, insurance, type of facility, comorbidity score, grade, histology, presence of distant metastatic disease, nephrectomy status, and receipt of systemic therapy, the HR for death in AAs compared with Caucasians was 1.10 (95% CI, 1.04-1.15) in the pretargeted therapy period and 1.13 (95% CI, 1.08-1.19) in the post-targeted therapy period. A substantial number of patients in the pretargeted era had missing comorbidity information; and, when those patients were excluded from the analysis, the HR remained unchanged (1.08 in the pretargeted therapy era vs 1.13 in the post-targeted therapy era). In the post-targeted therapy period, the HR for death remained significant when adjusting for baseline T and N classification (HR, 1.14; 95% CI, 1.06-1.21). Other factors associated with survival are listed in Table 3 .
DISCUSSION
Our study demonstrates that both AA and Caucasian patients with advanced RCC have had a significant increase in the rate of systemic treatment, with an accompanying improvement in survival, since the advent of targeted therapy. However, a disparity in survival persists between races even after controlling for treatment differences, such as nephrectomy status and receipt of systemic therapy. This suggests that the racial disparity in survival may be related to factors unaffected by the implementation of targeted therapy and that treatment bias does not explain the survival disparity.
Our survival analysis is in agreement with other recently published studies in advanced RCC. Pal et al published a Surveillance, Epidemiology, and End Results analysis of patients with metastatic RCC and observed an improvement in median disease-specific survival between 1992 and 2009, with shorter survival for AA patients compared with Caucasian patients. 6 Vaishampayan et al also demonstrated an improvement in overall survival over time, although the change in survival of AA patients over the same period was not significant in their study. 5 Therefore, to our knowledge, ours is the first study to demonstrate an overall survival improvement among AA patients with advanced RCC since the advent of targeted therapy. The proportion of patients receiving systemic therapy for advanced RCC did not approach the most recent levels until 2007, suggesting that, in the report by Vaishampayan et al, the post-targeted therapy group from 2005 through 2008 may have been analyzed for survival too early in the history of targeted therapy to observe an effect. The difference in improvement among AA patients between our study and the study by Vaishampayan and colleagues also potentially may be explained by differential rates of implementation between AAs and Caucasians, but we did not observe evidence of this in our analysis. We believe that the lack of statistical significance of an improvement in survival of AA patients who received systemic treatment and had clear cell histology is related to the drastically reduced sample size of this population, given the overall similar magnitude of benefit across time in this population.
It should also be noted that the survival rates in our study were lower than expected based on clinical trials of targeted therapy in patients with RCC. Our population had a large proportion of patients who had distant metastases at diagnosis compared with patients in the Vaishampayan et al analysis (70.8% vs 52.7%, respectively). These findings emphasize the poor survival associated with stage IV RCC in the general population. 5, [11] [12] [13] Among patients who actually received systemic therapy in our analysis, the survival rates were similar to those reported in poor-risk metastatic RCC trials. 14 The cause of the persistent disparity in survival among AA patients compared with Caucasians has not been defined. Several studies have suggested access to care and nephrectomy rates as potential explanations. 3, 6, 7 To control for this possibility, we designed our study using the NCDB, which is annotated for treatment received.
Unlike prior studies, we were able to account for receipt of systemic therapy in our analysis and identified a persistent survival disparity among patients who received systemic therapy. We did observe that AA patients were more likely to have distant metastatic disease (M1), which may contribute to the survival disparity and may also suggest a delay in diagnosis in AA patients. Although it was not possible to control for timeliness of diagnosis, we did control for the presence of distant metastatic disease as well as the time to initiation of systemic therapy and the time to nephrectomy. Therefore, our analyses suggest that racial differences in socioeconomic status or access to care are unlikely to explain the current findings. Supporting this conclusion is a study by Tripathi et al, who retrospectively examined racial disparities in patients with RCC who were enrolled in clinical trials in an effort to eliminate socioeconomic status and treatment choice as potential confounders. Those authors also observed that overall survival remained statistically shorter for AAs than for Caucasians in this setting. 4 Therefore, when taken together with prior studies, our study supports that differences in tumor biology other than standard histology could potentially explain these findings. We observed that, as reported previously, AA patients were more likely to have papillary histology than Caucasian patients. 15, 16 Nonclear cell histology is associated with inferior survival in patients with advanced RCC 17 ; therefore, we controlled for histology in our analysis. Our rates of nonclear cell histology were slightly lower than the expected rates from previous literature, and this difference may be related to the high rate of "unknown" histology designations in our study and potentially could confound our results. 18 However, a survival disparity between races exists even within each subtype, and this would not fully explain our findings. 2 On the basis of data from The Cancer Genome Atlas, our group recently demonstrated that tumors from AA patients who have clear cell RCC are less likely to harbor von Hippel-Lindau (VHL) mutations, have lower RNA expression of hypoxia-inducible factor and VEGFassociated pathways, and are more likely to have the more aggressive clear cell B subtype. 19 These differences suggest that AAs with clear cell RCC may be less likely to respond to VEGF-targeted therapy and that differences in tumor biology may drive some of the observed survival disparity. Our current study supports the potential role of tumor biology in the racial disparity in survival, because, after adjustment for clinical factors, the survival disparity persists between races. However, it does not support the idea that AAs have an inferior response to VEGF-targeted therapy. There could be several reasons for this finding. The NCDB does not differentiate between types of systemic therapy received; therefore, it is possible that the use of mTOR inhibitors or other non-VEGF-targeted therapies are driving the improved survival observed in AA patients. Alternatively, is possible that, despite lower rates of VHL mutations and differences in downstream gene expression, AAs may retain sensitivity to VEGF-targeted therapy. Indeed, VHL status and VEGF expression are not reliable predictors of response to VEGF pathway inhibition, and VHL loss may be influencing survival rates in a VEGFindependent manner. 20, 21 There are several limitations to our current analysis. Inherent to any study using the NCDB, the data presented here are not truly population-based, because patients are drawn from certain designated Commission on Cancer hospitals. Despite this, we believe the current analysis is likely reflective of the true trends in outcomes, because these data encompass the majority of diagnosed cases in the United States over the period studied and come from a wide array of settings. A strength of this study is the ability to restrict the analysis to patients who actually received systemic therapy. However, we were unable to confirm that the systemic therapy received was in fact targeted therapy or which agent was used. We were also unable to confirm actual receipt, because it is possible that tolerability may differ between races. The NCDB also does not collect data on performance status, and the Charlson Comorbidity Index is a validated, but not comprehensive, tool with which to assess comorbidities. We also could not account for all of the variables in the commonly used prognostic scoring systems in metastatic RCC because of inherent NCDB limitations, such as a lack of reporting on laboratory values. Therefore, unmeasured confounders may have influenced our results, although we attempted to minimize this possibility by restricting our analyses to the treated patients who were more likely to have similar performance status and comorbidities.
We conclude that targeted therapy has been effective in improving survival in both AA and Caucasian patients with advanced RCC. However, there remains a survival disparity between races that is independent of other prognostic factors and nephrectomy status, and it even exists within patients who actually received systemic therapy. Further studies should focus on the differences in tumor biology between races, which may be independent of the VEGF pathway given the lack of differential survival improvement between races on a population level. 
